India Active Pharmaceutical Ingredients Market Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Method of Synthesis (Synthetic, Biological), By Source (Contact Manufacturing Organizations, In-house Manufacturing), By Therapeutic Application (Cardiovascular Diseases, Anti-diabetic Drugs, Oncology Drugs, Neurological Disorders, Musculoskeletal Disorders, Others), By Drug Type (G
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationIndia Active Pharmaceutical Ingredients Market Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Method of Synthesis (Synthetic, Biological), By Source (Contact Manufacturing Organizations, In-house Manufacturing), By Therapeutic Application (Cardiovascular Diseases, Anti-diabetic Drugs, Oncology Drugs, Neurological Disorders, Musculoskeletal Disorders, Others), By Drug Type (G
| Forecast Period | 2026-2030 |
| Market Size (2024) | USD 13.60 Billion |
| Market Size (2030) | USD 21.99 Billion |
| CAGR (2025-2030) | 8.30% |
| Fastest Growing Segment | In-house Manufacturing |
| Largest Market | North India |
Market Overview
India Active Pharmaceutical Ingredients Market was valued at USD 13.60 Billion in 2024 and is anticipated to reach USD 21.99 Billion by 2030, with a CAGR of 8.30% during 2025-2030.
Indian pharmaceutical firms heavily invest in R&D to develop novel APIs, driving market growth. With a sizable and expanding domestic market, India experiences high demand for APIs for both generic and innovative drugs. Offering custom synthesis and contract manufacturing services further boosts the API market by enabling close collaboration with clients for specific API development. Additionally, the globalization of pharmaceutical supply chains has broadened the market reach of Indian API manufacturers, who export to various international markets, fueling further growth.
Key Market Drivers
Rise in Domestic Pharmaceutical Market
India boasts one of the world's largest populations, with substantial healthcare needs encompassing disease treatment, chronic condition management, and healthcare maintenance. The widespread use of generic medications, driven by their affordability, is a significant factor in the country's healthcare landscape. APIs are integral to these generics, with their demand being a key driver for API production. The affordability of generic drugs, enabled by their API components, ensures broad accessibility to essential medications, thereby amplifying demand.
As India's economy expands and disposable incomes rise, healthcare spending has seen a corresponding increase, spurring demand for various pharmaceutical products, including those reliant on APIs. Government healthcare initiatives like the National Health Mission further bolster this demand by enhancing healthcare access and services. The surge in chronic diseases such as diabetes, cardiovascular conditions, and respiratory ailments necessitates a steady API supply for producing relevant medications.
The burgeoning middle class in India, with heightened healthcare expectations and improved access to medical treatments, constitutes a significant demographic driving demand for pharmaceuticals and APIs. Increased healthcare awareness and emphasis on early diagnosis and treatment further augment this demand. The expansion of health insurance coverage across India has democratized healthcare, making it more accessible and affordable, thereby escalating demand for pharmaceutical products.
Increasing Demand of Custom Synthesis and Contract Manufacturing
Custom synthesis and contract manufacturing services empower pharmaceutical firms to access APIs tailored precisely to their unique specifications. This customization is vital for crafting proprietary drug formulations and pioneering medications. Leveraging specialized providers of custom synthesis and contract manufacturing offers pharmaceutical companies efficiency gains and cost advantages. These providers typically boast streamlined processes and specialized expertise, resulting in economical API production.
Deep-seated understanding of chemical processes and intricate API synthesis distinguishes these service providers. Such expertise proves invaluable for pharmaceutical companies aiming to innovate in drug development or enhance existing formulations. Outsourcing API production to these providers expedites drug development timelines, enabling companies to concentrate on research, development, and commercialization while entrusting API manufacturing to capable partners. By doing so, pharmaceutical firms mitigate risks tied to API manufacturing, such as supply chain disruptions and regulatory changes, while upholding stringent quality control standards.
Global outreach of API manufacturers offering custom synthesis and contract manufacturing services benefits pharmaceutical firms with international operations. Collaborating with these partners safeguards intellectual property rights, particularly in developing proprietary formulations. These providers offer a diverse array of APIs across therapeutic areas and often engage in collaborative research and development efforts, fostering innovation. Such dynamics are poised to propel the demand for the India Active Pharmaceutical Ingredients Market.
Growing Research and Development
Pharmaceutical research and development (R&D) primarily aim to discover and develop new drugs, driving demand for specific APIs sourced or synthesized for these drugs. R&D focuses on innovating drug formulations and delivery systems, often necessitating novel APIs. Ongoing efforts in R&D aim to enhance the efficacy, safety, and patient experience of existing drugs, potentially leading to modified APIs or new production processes. The trend toward personalized medicine further increases API demand, as treatments are tailored to individuals' genetic profiles.
The growth of biopharmaceuticals, including biologics and biosimilars, relies on R&D to develop corresponding APIs like monoclonal antibodies and recombinant proteins. Advanced therapies such as gene and cell therapies also require specialized APIs, contributing to API demand. Clinical trials, crucial for drug development, drive API demand for trial supply and subsequent production.
Companies may invest in R&D for generic drug development post-patent expiry, leading to generic API production. Quality-driven R&D efforts ensure API safety, efficacy, and adherence to standards, fueling demand for high-quality ingredients. To stay competitive, companies invest in R&D to differentiate their products, driving the development of unique APIs. This trend is poised to accelerate demand in the India Active Pharmaceutical Ingredients Market.
Key Market Challenges
Quality Control and Assurance
Meeting the stringent quality standards and regulatory requirements of various international markets, such as the US FDA and the European Medicines Agency (EMA), is a continuous challenge. API manufacturers in India must invest in robust quality control and assurance processes to gain and maintain regulatory approvals. Maintaining consistent quality across different batches of APIs is a challenge. Variability in the quality of APIs can lead to manufacturing issues and may affect the safety and efficacy of the final drug product. The quality of raw materials, including starting materials and intermediates, is crucial for API production. Ensuring the quality and traceability of these materials can be challenging, especially when sourced from diverse suppliers. Ensuring compliance with Good Manufacturing Practices (GMP) standards is essential for API manufacturers. It requires a significant investment in infrastructure, equipment, training, and quality management systems. Recruiting and retaining skilled professionals with expertise in analytical chemistry, quality control, and quality assurance is a challenge. Highly qualified personnel are needed to implement quality control processes effectively.
Market Access Barriers
Meeting the stringent regulatory standards of various international markets, such as the US FDA and the European Medicines Agency (EMA), can be a significant barrier. API manufacturers must ensure that their facilities and processes adhere to these standards to gain market access. Maintaining consistent quality and adherence to Good Manufacturing Practices (GMP) is essential for market access. Variability in API quality can lead to rejection by regulatory authorities and customers. The protection of intellectual property rights can be a barrier when exporting APIs to certain markets. API manufacturers must navigate complex patent landscapes and intellectual property regulations to gain market access. Accurate and comprehensive documentation is crucial for regulatory approvals and market access. Ensuring that all required documents are in order can be a challenge. API manufacturers often face intense price competition in global markets. Ensuring cost competitiveness while maintaining quality can be a barrier. Trade barriers, such as tariffs and non-tariff barriers, can affect the export of APIs to specific countries. Negotiating these barriers can be a challenge. Complying with customs and import regulations in target markets can be complex and time-consuming, leading to delays and potential barriers.
Key Market Trends
Environmental Sustainability
Increasingly stringent environmental regulations require pharmaceutical manufacturers, including API producers, to adopt more sustainable and environmentally friendly production processes. Compliance with these regulations is essential for market access and reputation. The adoption of green chemistry principles is gaining traction. Green chemistry focuses on minimizing the environmental impact of chemical processes, reducing waste, and conserving resources. API manufacturers are seeking ways to optimize resource use, such as water and energy, to reduce their environmental footprint and operational costs. Minimizing waste generation and improving waste management practices is a priority. Sustainable waste handling, including the disposal of hazardous materials, is crucial. Some API manufacturers are transitioning to the use of renewable energy sources to power their production facilities, reducing greenhouse gas emissions. The pharmaceutical industry is showing an interest in sourcing raw materials and starting materials from suppliers who follow sustainable practices, including responsible sourcing of natural ingredients. Efforts to reduce the carbon footprint of API manufacturing are becoming more common, with initiatives to measure, report, and reduce greenhouse gas emissions. The concept of a circular economy, where resources and materials are recycled and reused, is being applied in the pharmaceutical industry, including the recycling of solvents and reusing waste products.
Segmental Insights
Method of Synthesis Insights
In 2024, the India Active Pharmaceutical Ingredients Market largest share was held by Synthetic segment and is predicted to continue expanding over the coming years.
Source Insights
In 2024, the India Active Pharmaceutical Ingredients Market largest share was held by Contact Manufacturing Organizations (CMO) segment and is predicted to continue expanding over the coming years.
Drug Type Insights
In 2024, the India Active Pharmaceutical Ingredients Market largest share was held by Generic Drug type
Regional Insights
The North India region dominates the India Active Pharmaceutical Ingredients Market in 2024.
Recent Developments
- In July 2023, Three Indian companies, Lupin, Natco, and Macleods, are preparing to produce generic versions of the TB drug Bedaquiline as its patent expires. While an exact timeline for the launch of Bedaquiline by these companies remains undefined due to the evolving global situation surrounding the drug, industry sources informed BusinessLine that some of them are currently in the process of obtaining local regulatory approvals.
- In April 2023, Two Indianpharmaceutical companies, Natco Pharma and MacLeods Pharmaceuticals, werepreparing to release their versions of Johnson & Johnson's groundbreakingtuberculosis (TB) drug, Bedaquiline. This J&J drug represents the firstglobal approval for TB treatment in approximately four decades, offering a lesstoxic and more effective alternative to traditional treatments. A key patentfor this drug is set to expire in July. Notably, securing an Emergency UseAuthorization (EUA) is contingent on the company's application for World HealthOrganization pre-qualification (PQ) and the submission of technical details.Attaining WHO PQ status will facilitate the adoption of the product by morecountries for their TB programs. Natco is also involved in the production ofboth the Active Pharmaceutical Ingredient (API) and the finished dosage form ofBedaquiline and is in the process of obtaining additional regulatory clearancesdue to the unique nature of this drug.
Key Market Players
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Dr. Reddy's LaboratoriesLtd.
- Sun PharmaceuticalIndustries Limited
- Cipla Limited
- Lupin Limited
- Aurobindo Pharma Limited
- Aarti Drugs Ltd.
- IOL Chemicals andPharmaceuticals Limited
- GSK plc
| By Method of Synthesis | By Source | By Therapeutics Application | By Drug Type | By Region |
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy